Ezetimibe: Perbedaan antara revisi

}}

 

 

Efek samping yang paling sering dilaporkan meliputi [[infeksi saluran napas atas]], [[nyeri]] sendi, diare, dan kelelahan.<ref name=AHFS2019/> Efek samping yang serius dapat meliputi [[anafilaksis]], masalah hati, depresi, dan kerusakan otot.<ref name=AHFS2019/><ref name=BNF76/> Penggunaan pada [[kehamilan]] dan [[menyusui]] tidak jelas keamanannya.<ref>{{cite web |title=Ezetimibe (Zetia) Use During Pregnancy |url=https://www.drugs.com/pregnancy/ezetimibe.html |website=Drugs.com |access-date=13 April 2019 |archive-date=13 April 2019 |archive-url=https://web.archive.org/web/20190413032023/https://www.drugs.com/pregnancy/ezetimibe.html |url-status=live }}</ref> Ezetimibe bekerja dengan mengurangi penyerapan kolesterol di usus.<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=196|edition=76}}</ref>

 

Ezetimibe disetujui untuk penggunaan medis di Amerika Serikat pada tahun 2002.<ref name="AHFS2019"/> Obat ini tersedia sebagai [[obat generik]].<ref name=BNF76/>

==Kegunaan dalam medis==

Penambahan ezetimibe pada pengobatan statin untuk [[hiperkolesterolemia|kolesterol darah tinggi]] tidak memiliki efek pada mortalitas keseluruhan atau mortalitas kardiovaskular, meskipun secara signifikan mengurangi risiko [[serangan jantung|infark miokard]] dan [[strok]].<ref>{{cite journal | vauthors = Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P | title = Safety and efficacy of ezetimibe: A meta-analysis | journal = International Journal of Cardiology | volume = 201 | pages = 247–252 | date = December 2015 | pmid = 26301648 | doi = 10.1016/j.ijcard.2015.08.103 }}</ref> Menggabungkan ezetimibe dengan [[simvastatin]] tidak memiliki efek pada mortalitas keseluruhan tetapi menurunkan risiko serangan jantung atau stroke pada orang dengan riwayat serangan jantung.<ref name=Phan/><ref>{{cite journal | vauthors = Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM | display-authors = 6 | title = Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | journal = The New England Journal of Medicine | volume = 372 | issue = 25 | pages = 2387–2397 | date = June 2015 | pmid = 26039521 | doi = 10.1056/NEJMoa1410489 | hdl-access = free | hdl = 11573/1150638 | doi-access = free | title-link = doi }}</ref> Beberapa pedoman pengobatan merekomendasikan penambahan ezetimibe pada orang berisiko tinggi tertentu yang target LDL-nya tidak dapat dicapai dengan statin yang ditoleransi secara maksimal saja.<ref name="AlenghatDavis2019">{{cite journal | vauthors = Alenghat FJ, Davis AM | title = Management of Blood Cholesterol | journal = JAMA | volume = 321 | issue = 8 | pages = 800–801 | date = February 2019 | pmid = 30715135 | pmc = 6679800 | doi = 10.1001/jama.2019.0015 }}</ref><ref>{{cite journal | vauthors = Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D | display-authors = 6 | title = ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) | journal = Atherosclerosis | volume = 217 | issue = 1 | pages = 3–46 | date = July 2011 | pmid = 21882396 | doi = 10.1016/j.atherosclerosis.2011.06.011 }}</ref><ref>{{cite journal | vauthors = Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K | display-authors = 6 | title = Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version | journal = Journal of Atherosclerosis and Thrombosis | volume = 20 | issue = 6 | pages = 517–523 | year = 2013 | pmid = 23665881 | doi = 10.5551/jat.15792 | doi-access = free | title-link = doi }}</ref><ref>{{cite web |url=http://www.nice.org.uk/Guidance/CG181++++ |title=Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease &#124; Guidance and guidelines &#124; NICE |archive-url=https://web.archive.org/web/20141119180833/http://www.nice.org.uk/guidance/CG181 |archive-date=19 November 2014 |url-status=dead }}</ref><ref>{{cite journal | title = An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report | journal = Journal of Clinical Lipidology | volume = 8 | issue = 1 | pages = 29–60 | year = 2014 | pmid = 24528685 | doi = 10.1016/j.jacl.2013.12.005 | doi-access = free | title-link = doi | vauthors = Grundy SM, Arai H, Barter P, Bersot TP, Betteridge DJ, Carmena R | collaboration=Expert Dyslipidemia Panel of the International Atherosclerosis Society }}</ref>